Clinical trials
Phase 2 COVID-19 trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 7 |
| 2021 | 11 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Terminated | 4 |
| Unknown status | 3 |
| Withdrawn | 3 |
| Recruiting | 3 |
| Suspended | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 3 |
| Pfizer | 2 |
| Appili Therapeutics Inc. | 1 |
| Canadian Immunization Research Network | 1 |
| Canadian Medical and Surgical Knowledge Translation Research Group | 1 |
| Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | 1 |
| Chris Miller | 1 |
| DalCor Pharmaceuticals | 1 |
| GlaxoSmithKline | 1 |
| Hoffmann-La Roche | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 27 |
| Coronavirus Infections | 5 |
| Post-Acute COVID-19 Syndrome | 2 |
| Abdominal Pain | 1 |
| Anemia, Sickle Cell | 1 |
| Anosmia | 1 |
| Arthralgia | 1 |
| Arthritis, Rheumatoid | 1 |
| Chest Pain | 1 |
| Confusion | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.